Tenaya Therapeutics to present new clinical data from RIDGE-1 Phase 1b/2 TN-401 trial at ASGCT

Tenaya Therapeutics to present new clinical data from RIDGE-1 Phase 1b/2 TN-401 trial at ASGCT
Tenaya shares TN-401 trial data

Tenaya Therapeutics announced plans to deliver a late breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) conference.

The presentation will feature new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial evaluating TN-401. This update is expected to provide insight into the ongoing development of TN-401 and Tenaya Therapeutics' broader efforts to advance gene therapies. Additional presentations by the company are also scheduled at the event.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.